PROTECmo Study: Thrombocytopenia in VenoVenous ECMO Linked to High Bleeding Risk
Marta Velia Antonini, Hematologist, Perfusionist ECMO and NRP Specialist and Chair of the Normothermic Regional Perfusion EuroELSO Working Group, shared on X:
”Thrombocytopenia in VV ECMO? Highly prevalent in VV ECMO, and strongly associated with bleeding risk and reduced survival.
Platelet transfusions do not appear to significantly reduce bleeding risk: targeted prevention strategies needed!
- Adults with respiratory failure; baseline thrombocytopenia 27.9%, mild 14.7%, moderate 8.7%, severe 4.4%
- Thrombocytopenia in ECLS occurred at least once in 80.2%; mild 21.3%, moderate 32.2%, severe 26.7%
- Mild thrombocytopenia increased risk of bleedings by 61%; moderate and severe by 90%
- Risk for thrombocytopenia increased with ICU days prior to ECMO, postop admission, immunocompromised state, RRT, septic shock, low hemoglobin, circuit replacement.”
Read the full article in Critical Care.
Title: Incidence, kinetics, and clinical impact of thrombocytopenia in venovenous ECMO: insights from the multicenter observational PROTECMO study
Authors: Nina Buchtele, Kenichi Tanaka, Fabio Tuzzolino, Cara Agerstrand, Ali Ait Hssain, Jordi Riera, Peter Schellongowski, Matthieu Schmidt, Raj Ramanan, Martin Balik, Lars Mikael Broman, Nicolo Rizzitello, Konstanty Szułdrzyński, Whitney D. Gannon, Vito Fanelli, Brian Trethowan, Hergen Buscher, Huda Alfoudri, Marco Giani, Alain Combes, Giacomo Grasselli, Roberto Lorusso, Antonio Arcadipane, Daniel Brodie, Gennaro Martucci, PROTECMO Study group
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals